Severe Dermatologic Reactions Reported After Treatment with Tocainide
Authors: JANET B. ARROWSMITH
Journal: Annals of Internal Medicine (1987)

Brief Reports1 November 1987Severe Dermatologic Reactions Reported After Treatment with TocainideJANET B. ARROWSMITH, M.D., JOYCE I. CREAMER, B.S.N., LYNN BOSCO, M.D., M.P.H.JANET B. ARROWSMITH, M.D.Search for more papers by this author, JOYCE I. CREAMER, B.S.N.Search for more papers by this author, LYNN BOSCO, M.D., M.P.H.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-107-5-693 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTocainide is a class I antiarrythmic drug with electrophysiologic characteristics similar to those of lidocaine. It is administered orally for suppression of symptomatic ventricular arrhythmias. Tocainide has been marketed in the United States since November 1984. (Tonocard; Merck Sharp & Dohme, West Point, Pennsylvania. The use of trade names is for purposes of product identification only and is not intended as product endorsement by the Food and Drug Administration [FDA] or the Department of Health and Human Services.) Among the well-recognized, serious adverse reactions reported after tocainide are blood dyscrasias and pulmonary fibrosis (1). We report a possible association between...References1. Physician's Desk Reference. Oradell, New Jersey: Medical Economics Co.; 1987: 1342-4. Google Scholar2. FAICH G. Adverse-drug-reaction monitoring. N Engl J Med. 1986;314:1589-92. CrossrefMedlineGoogle Scholar3. ELIASFRITSCH PP. Erythema multiforme. In: FITZPATRICK TB, et al, eds. Dermatology in General Medicine. 2nd ed. New York: McGrawHill; 1979: 295-303. Google Scholar4. HUFFWESTONTONNESEN JWM. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol. 1983;8:763-75. CrossrefMedlineGoogle Scholar5. LENNON D. Co-trimoxazole toxicity [Letter]. Lancet. 1984;2:1152. CrossrefMedlineGoogle Scholar6. MILLERLOBELSATRIALEKURITSKYSTERNCAMPBELL KHRJRC. Severe cutaneous reactions among American travelers using pyramethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg. 1986;35:451-8. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JANET B. ARROWSMITH, M.D.; JOYCE I. CREAMER, B.S.N.; LYNN BOSCO, M.D., M.P.H.Affiliations: U.S. Food and Drug Administration Rockville, Maryland PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byClass I Antiarrhythmic DrugsAdverse Dermatologic Effects of Cardiovascular Drug Therapy: Part IVIRAL INFECTIONS IN THE IMMUNOCOMPETENT PATIENTAdverse Dermatologic Reactions from Antiarrhythmic Drug TherapyErythema multiforme: a literature review and case reportEvaluation of early signals of drug-induced stevens-johnson syndrome in the WHO ADR databaseSystemic local anesthetics in pain controlPoisoning Due to Class 1B Antiarrhythmic DrugsVerapamil-Associated Stevens-Johnson SyndromePilot Study of the Potential Benefit of Tocainide in the Management of Ciguatera ToxicityPotential benefit of tocainide in the treatment of ciguatera: Report of three cases 1 November 1987Volume 107, Issue 5Page: 693-696KeywordsAdverse reactionsArrhythmiaBloodDrugsFood and Drug AdministrationHealth services administration and managementPulmonary fibrosis ePublished: 1 December 2008 Issue Published: 1 November 1987 PDF downloadLoading ...